血脑屏障功能障碍和阿尔茨海默病:关联,致病机制和治疗潜力
Yanting Chen1, Yanfang He2, Jinling Han1
1Department of Neurology, Shenzhen Sixth People's Hospital, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China.
Frontiers in aging neuroscience
|November 29, 2023
概括
阿尔茨海默病涉及大脑变化,如粉样β和陶积累. 本综述探讨了血脑屏障 (BBB) 功能障碍如何导致阿尔茨海默病的进展以及潜在的BBB向疗法.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学科学 生物医学科学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样β (Aβ) 斑块,高酸化,以及神经炎症.
- 血脑屏障 (BBB) 对大脑功能至关重要,但其在AD病变发生过程中的改变仍然不清楚.
- 了解BBB变化对于早期发现AD和开发向治疗来说至关重要.
研究的目的:
- 总结目前关于阿尔茨海默病 (AD) 中血脑屏障 (BBB) 功能障碍的证据.
- 分析将BBB功能障碍与AD风险因素 (Aβ,tau,神经炎症,ApoE,衰老) 联系在一起的致病机制.
- 讨论针对AD治疗的BBB的当前和未来治疗策略.
主要方法:
- 关于阿尔茨海默病和血脑屏障功能的现有科学文献的全面审查.
- 分析BBB功能障碍与AD主要病理特征和风险因素之间的相互关系.
- 综合当前的治疗方法和未来的研究方向,用于针对BBB的AD干预.
主要成果:
- 有证据表明,在阿尔茨海默病 (AD) 进展中,血脑屏障 (BBB) 功能障碍显著.
- BBB的变化与β-粉样蛋白,tau病理,神经炎症,ApoE基因型和衰老密切相关.
- 准BBB为新型阿尔茨海默病治疗提供了一个有希望的途径.
结论:
- 血脑屏障 (BBB) 功能障碍是阿尔茨海默氏症 (AD) 病变发生的关键组成部分.
- 阐明BBB变化的机制对于推动AD研究和治疗至关重要.
- 专注于BBB的治疗策略具有延缓AD进展和改善患者结果的巨大潜力.
相关概念视频
The Blood-brain Barrier
47.4K
Overview
47.4K
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


